1. Generics Bulletin
  2. >>Business
  3. >>Deals

Sawai Ends American Dream With Upsher-Smith Sale

Bora Strikes $210m Deal For US Unit; Sawai Cites Buyer Consolidation And Indian Competition

 
• By Dave Wallace

Japanese generics giant Sawai is pulling out of the US market, agreeing a deal to divest its Upsher-Smith business to Taiwan’s Bora Pharmaceuticals in a deal worth a little over $200m. As Sawai explained its rationale for the move, Bora pointed to “significant opportunities” for its TWi commercial prescription unit arising from the acquisition.

USA and Japan flags ripped apart
Sawai is selling its US Upsher-Smith business to focus on Japan • Source: Shutterstock

Sawai Pharmaceutical has agreed to sell its Upsher-Smith Laboratories business to Taiwan’s Bora Pharmaceuticals in a deal worth up to $210m, bringing to an end a near seven-year sojourn in the US market for the Japanese generics giant.

Announcing the divestment – which is subject to customary regulatory approvals – Sawai cited factors including buyer consolidation and competition from Indian rivals, as well as the need to focus on its domestic

Key takeaways:

  • Japan’s Sawai has agreed to sell its US Upsher-Smith business to Taiwan’s Bora in a deal worth up to $210m.

  • Upsher-Smith was acquired for $1.05bn by Sawai back in 2017.

  • Factors influencing Sawai’s decision to sell included competitive pressures from US purchaser consolidation and Indian rivals, as well as the need to focus on Japan

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

More from Business

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.